US Bancorp DE Sells 21,641 Shares of Solventum Corporation $SOLV

Key Points

• US Bancorp DE reduced its stake in Solventum Corporation by 4.6%, selling 21,641 shares, leaving it with 451,102 shares valued at approximately $34.2 million.
• Research analysts have given Solventum a mixed rating, with one "Strong Buy," three "Buy," and seven "Hold" ratings, leading to a consensus price target of $84.89.
• Solventum reported a profit of $1.69 per share for its latest quarter, exceeding analysts' expectations, and projected annual earnings per share for FY 2025 between $5.800 and $5.950.

US Bancorp DE lessened its holdings in Solventum Corporation (NYSE:SOLV - Free Report) by 4.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 451,102 shares of the company's stock after selling 21,641 shares during the period. US Bancorp DE owned approximately 0.26% of Solventum worth $34,212,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of SOLV. Rossby Financial LCC bought a new stake in Solventum in the first quarter worth $25,000. Strengthening Families & Communities LLC increased its position in Solventum by 376.8% in the first quarter. Strengthening Families & Communities LLC now owns 329 shares of the company's stock worth $25,000 after purchasing an additional 260 shares during the last quarter. Barrett & Company Inc. increased its position in Solventum by 206.2% in the second quarter. Barrett & Company Inc. now owns 398 shares of the company's stock worth $30,000 after purchasing an additional 268 shares during the last quarter. Hara Capital LLC bought a new stake in Solventum in the first quarter worth $38,000. Finally, Smartleaf Asset Management LLC increased its position in Solventum by 193.4% in the first quarter. Smartleaf Asset Management LLC now owns 534 shares of the company's stock worth $40,000 after purchasing an additional 352 shares during the last quarter.

Analyst Ratings Changes

A number of research analysts have weighed in on SOLV shares. Wells Fargo & Company boosted their price objective on shares of Solventum from $79.00 to $82.00 and gave the company an "equal weight" rating in a research report on Monday, September 15th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Solventum in a research report on Wednesday. Morgan Stanley upgraded shares of Solventum from an "equal weight" rating to an "overweight" rating and boosted their price objective for the company from $80.00 to $103.00 in a research report on Tuesday, July 15th. Zacks Research upgraded shares of Solventum from a "hold" rating to a "strong-buy" rating in a research report on Monday, September 15th. Finally, Argus upgraded shares of Solventum from a "hold" rating to a "buy" rating and set a $90.00 price objective on the stock in a research report on Tuesday, July 1st. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $84.89.

Solventum Stock Down 1.8%

NYSE:SOLV opened at $70.53 on Friday. Solventum Corporation has a 1-year low of $60.70 and a 1-year high of $85.92. The company has a 50-day moving average of $72.75 and a 200 day moving average of $72.11. The firm has a market cap of $12.23 billion, a PE ratio of 32.65, a price-to-earnings-growth ratio of 2.92 and a beta of 0.50. The company has a debt-to-equity ratio of 2.14, a current ratio of 1.22 and a quick ratio of 0.86.

Solventum (NYSE:SOLV - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, topping analysts' consensus estimates of $1.45 by $0.24. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The company had revenue of $2.16 billion during the quarter, compared to analyst estimates of $2.12 billion. During the same period in the prior year, the firm earned $1.56 earnings per share. The firm's revenue for the quarter was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. As a group, research analysts anticipate that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.